Nasal compression device for treating nosebleeds
Feasibility Study of a Nasal Compression Device in Comparison to Digital Nasal Compression for Stopping Epistaxis
This study is testing a new nasal compression device to see if it works better than the usual method for stopping nosebleeds in people who have them.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 40 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | NasaClip Industry-sponsored |
| Locations | 1 site (Houston, Texas) |
| Trial ID | NCT05789264 on ClinicalTrials.gov |
What this trial studies
This study compares the effectiveness of a nasal compression device to standard manual compression for stopping anterior nosebleeds. Participants presenting with nosebleeds will be assigned to either the nasal compression device group or the standard care group. The study will assess bleeding resolution and gather participant feedback on comfort and satisfaction with the treatment received. Evaluations will occur every 5-10 minutes to monitor bleeding status and determine treatment success.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older presenting with anterior epistaxis who are in good general health.
Not a fit: Patients with known allergies to the device components, those under 18, or individuals with certain medical conditions may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide a more effective and comfortable method for managing anterior nosebleeds.
How similar studies have performed: While similar approaches have been explored, this specific comparison of a nasal compression device to standard care is novel.
Eligibility criteria
Show full inclusion / exclusion criteria
INCLUSION In order to be eligible to participate in this study, an individual must meet all of the following criteria: 1. Presenting with anterior epistaxis determined as someone with venous bleeding that can be controlled with external compression. 2. Stated willingness to comply with all study procedures and availability for the duration of the study. 3. Male or female, aged at least 18. 4. In good general health as determined by the PI or Sub-I(s). EXCLUSION An individual who meets any of the following criteria will be excluded from participation in this study: 1. Known allergic or hypersensitivity reactions to components of NasaClip or oxymetazoline. 2. Less than 18 years of age. 3. Known pregnancy. 4. Unable to provide informed consent. 5. Subjects who are prisoners or who are in police custody. 6. Identified by the medical team as having an acute exacerbation or poor control of any of the following medical conditions: high blood pressure, heart disease, thyroid disease, diabetes, trouble urinating due to an enlarged prostate. 7. Patients taking MAO inhibitors. 8. Medical instability or need for emergent intervention as determined by on-site medical team.
Where this trial is running
Houston, Texas
- Next Level Urgent Care — Houston, Texas, United States (Recruiting)
Study contacts
- Study coordinator: Wilner Jeudy, Dr.
- Email: wjeudy@nextlevelurgentcare.com
- Phone: 281-612-3600
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.